/LTRN
LTRN Stock - Lantern Pharma Inc.
Healthcare|BiotechnologyNASDAQ
$3.26+0.62%
+$0.02 (+0.62%) • Dec 19
50
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.16
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.56
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.59
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LTRN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$3.23 – $3.29
TARGET (TP)$3.75
STOP LOSS$3.00
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.60
52W High$6.12
52W Low$2.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-174,843 | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-22,216,437 | $-17,877,570 | $-14,432,753 | $-12,591,508 | $-5,908,190 |
| Net Income | $-20,781,213 | $-15,961,534 | $-14,259,946 | $-12,363,029 | $-5,908,190 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1930.92 | $-1.47 | $-1.31 | $-1.13 | $-0.95 |
Company Overview
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LTRNBeat Rate
74%
Last 19 quarters
Avg Surprise
+12.1%
EPS vs Estimate
Beats / Misses
14/5
Last 12 quarters
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q1 24
+2.5%
$-0.39vs$-0.40
Q2 24
-18.6%
$-0.51vs$-0.43
Q3 24
+16.4%
$-0.46vs$-0.55
Q4 24
+25.0%
$-0.42vs$-0.56
Q1 25
-5.9%
$-0.54vs$-0.51
Q2 25
+14.3%
$-0.42vs$-0.49
Q3 25
+24.5%
$-0.40vs$-0.53
Q4 25
+15.2%
$-0.39vs$-0.46
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 13, 2026 | — | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.46 | $-0.39 | +15.2% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.53 | $-0.40 | +24.5% | ✓ BEAT |
Q2 2025 | May 15, 2025 | $-0.49 | $-0.42 | +14.3% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.51 | $-0.54 | -5.9% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.56 | $-0.42 | +25.0% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.55 | $-0.46 | +16.4% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.43 | $-0.51 | -18.6% | ✗ MISS |
Q1 2024 | Mar 18, 2024 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q4 2023 | Nov 8, 2023 | $-0.45 | $-0.29 | +35.6% | ✓ BEAT |
Q3 2023 | Aug 9, 2023 | $-0.43 | $-0.44 | -2.3% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-0.48 | $-0.36 | +25.0% | ✓ BEAT |
Q1 2023 | Mar 20, 2023 | $-0.47 | $-0.31 | +34.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.48 | $-0.21 | +56.3% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.52 | $-0.41 | +21.2% | ✓ BEAT |
Q2 2022 | May 3, 2022 | $-0.29 | $-0.38 | -31.0% | ✗ MISS |
Q1 2022 | Mar 10, 2022 | $-0.40 | $-0.32 | +20.0% | ✓ BEAT |
Q4 2021 | Nov 1, 2021 | $-0.27 | $-0.36 | -33.3% | ✗ MISS |
Q3 2021 | Jul 29, 2021 | $-0.26 | $-0.21 | +19.2% | ✓ BEAT |
Q2 2021 | May 3, 2021 | $-0.27 | $-0.24 | +11.1% | ✓ BEAT |
Latest News
Lantern Pharma Reports Additional LP-184 Phase 1a Results Showing 54% Disease Control Rate In Heavily Pre-Treated Advanced Cancer Patients
📈 PositiveBenzinga•Dec 3, 2025, 01:35 PM
Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate
📈 PositiveBenzinga•Nov 13, 2025, 11:03 AM
Lantern Pharma To Showcase Two Of Its Commercially Deployed AI Research Platforms At The Inaugural AI For Biology And Medicine Symposium At The University Of North Texas
📈 PositiveBenzinga•Oct 30, 2025, 12:11 PM
Lantern Pharma Presents Clinical Data From Ongoing Phase 1 Trial Of LP-284, At LL&M Congress, Featuring Metabolic Response In Aggressive DLBCL Case After Multiple Failed Therapies
📈 PositiveBenzinga•Oct 28, 2025, 12:51 PM
Watching Lantern Pharma; Shares Move Higher, Traders Circulate FDA News Reported September 16, 2025
📈 PositiveBenzinga•Sep 30, 2025, 08:25 PM
Trading Halt: Halt status updated at 8:40:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Sep 16, 2025, 12:40 PM
Lantern Pharma's LP-184 Meets All Phase 1a Endpoints, Shows Clinical Benefit In Hard-to-Treat Cancers And Advances To Phase 2 Trials
📈 PositiveBenzinga•Sep 16, 2025, 12:30 PM
Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Sep 16, 2025, 12:25 PM
Lantern Pharma Says FDA Confirms Potential Incorporation Of Spironolactone As Combination Agent In Trial; Plans Ind Amendment Submission & Trial Initiation For Pediatric CNS Cancer Trial In Q1 2026
📈 PositiveBenzinga•Sep 3, 2025, 01:51 PM
Lantern Pharma Completes Type C Meeting With FDA, Advancing Pediatric CNS Cancer Trial Including Atypical Teratoid Rhabdoid Tumor
📈 PositiveBenzinga•Sep 3, 2025, 01:47 PM
Lantern Pharma Narrows Loss in Q2
📈 PositiveThe Motley Fool•Aug 13, 2025, 10:18 PM
Frequently Asked Questions about LTRN
What is LTRN's current stock price?
Lantern Pharma Inc. (LTRN) is currently trading at $3.26 per share. The stock has moved +0.62% today.
What is the analyst price target for LTRN?
No analyst price targets are currently available for this stock.
What sector is Lantern Pharma Inc. in?
Lantern Pharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is LTRN's market cap?
Lantern Pharma Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does LTRN pay dividends?
No, Lantern Pharma Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorANVS
Annovis Bio, Inc.
$3.65
Mkt Cap: $0.1B
ATNM
Actinium Pharmaceuticals, Inc.
$1.69
Mkt Cap: $0.1B
BCAB
BioAtla, Inc.
$0.75
Mkt Cap: $0.0B
CALC
CalciMedica, Inc.
$6.35
Mkt Cap: $0.1B
ELUT
Elutia Inc.
$0.59
Mkt Cap: $0.0B
LVTX
LAVA Therapeutics N.V.
$1.74
Mkt Cap: $0.0B
MAIA
MAIA Biotechnology, Inc.
$1.22
Mkt Cap: $0.0B
RNXT
RenovoRx, Inc.
$0.93
Mkt Cap: $0.0B
RVPH
Reviva Pharmaceuticals Holdings, Inc.
$0.60
Mkt Cap: $0.0B
TVRD
Tvardi Therapeutics, Inc.
$3.98
Mkt Cap: $0.0B
Explore stocks similar to LTRN for comparison